2023年第1版《NCCN胸腺瘤和胸腺癌临床实践指南》解读

Interpretationof NCCNguidelinesyersion 1.2023 thymomas and thymic carcinomas

日前,美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)发布了2023年第1版《NCCN胸腺瘤和胸腺癌临床实践指南》(以下简称《指南》)。《指南》以最新研究进展及高质量的临床证据为理论基础,综合考虑制定胸腺瘤和胸腺癌的诊治标准。相比于2022年第1版《指南》,后续2个版本均有不少更新、修订,主要集中在放疗原则、系统全身治疗原则、多学科参与和一些脚注的完善补充等方面。本文将对《指南》内容进行逐一解读,以期为我国现阶段胸腺瘤和胸腺癌相关工作提供参考。

National Comprehensive Cancer Network(NCCN)has updated and released the latest content of NCCN guidelines version 1.2023 thymomas and thymic carcinomas(known as"guidelines").The guideline sets standards for the diagnosis and treatment of thymoma and thymic carcinoma based on high quality clinical evidence and the latest advances in research.There have been some updates and revisions in the latest two versions of the guidelines,mainly focusing on the principles of radiotherapy,the principles of systematic therapy,multidisciplinary participation and the improvement of some footnotes,compared with the first version of the guidelines in 2022.In this paper,the contents of the new guideline will be interpreted in order to provide reference for the work of thymoma and thymic carcinoma in our country at the present stage.